AIS	adenocarcinoma in situ
ALK	anaplastic lymphoma kinase
ATORG	Asian Thoracic Oncology Research Group
cfDNA	cell-free DNA
CHIP	clonal hematopoiesis of indeterminate potential
CI	confidence interval
CT	computed tomography
ctDNA	circulating tumor DNA
DFS	disease-free survival
EFS	event-free survival
EGFR	epidermal growth factor receptor
FDA	U.S. Food and Drug Administration
HR	hazard ratio
LOD	limit of detection
MIA	minimally invasive adenocarcinoma
MRD	molecular residual disease
NPV	negative predictive value
NSCLC	non-small-cell lung cancer
OS	overall survival
pCR	pathologic complete response
PD-L1	programmed death-ligand 1
ppm	parts per million
RET	rearranged during transfection
RFS	recurrence-free survival
VAF	variant allele frequency
WGS	whole-genome sequencing